MorphySys AG increased its revenue by 44% to €16.9 million in the first quarter of 2013 primarily due to a license payment from the purchaser of its AbD Serotec service business. The German company swung into a profit after a year-earlier loss. ---Subscribe to MedNous to access this article--- Company News
